1.43

1.42% 0.02

Repare Therapeutics Inc (RPTX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$1.41

Offen:

$1.41

24-Stunden-Volumen:

181.24K

Relative Volume:

0.61

Marktkapitalisierung:

$53.14M

Einnahmen:

$51.13M

Nettoeinkommen (Verlust:

$-93.80M

KGV:

-0.6413

EPS:

-2.23

Netto-Cashflow:

$-129.10M

1W Leistung:

+14.40%

1M Leistung:

+33.64%

6M Leistung:

-60.06%

1J Leistung:

-57.31%

1-Tages-Spanne:

$1.41

$1.48

1-Wochen-Bereich:

$1.2601

$1.48

52-Wochen-Spanne:

$0.89

$4.29

Repare Therapeutics Inc Stock (RPTX) Company Profile

Firmenname

Repare Therapeutics Inc

Sektor

Healthcare (1153)

Branche

Biotechnology (662)

Telefon

(857) 412-7018

Adresse

7171 FREDERICK BANTING, SAINT-LAURENT, QC

Mitarbeiter

129

Twitter

@reparerx

Nächster Verdiensttermin

2023-08-09

Neueste SEC-Einreichungen

RPTX's Discussions on Twitter

Vergleichen Sie RPTX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPTX Repare Therapeutics Inc	1.43	53.14M	51.13M	-93.80M	-129.10M	-2.23
VRTX Vertex Pharmaceuticals Inc	501.90	126.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.10	65.06B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	650.09	37.54B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	260.20	32.56B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	256.53	26.40B	3.81B	-644.79M	-669.77M	-6.24

Repare Therapeutics Inc Stock (RPTX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-06-09	Hochstufung	Stifel	Hold → Buy
2023-02-03	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-01-06	Eingeleitet	CapitalOne	Overweight
2022-04-12	Herabstufung	Stifel	Buy → Hold
2022-03-17	Fortgesetzt	Goldman	Buy
2021-09-23	Eingeleitet	Stifel	Buy
2021-09-13	Eingeleitet	H.C. Wainwright	Buy
2021-06-28	Eingeleitet	Guggenheim	Buy
2021-03-01	Eingeleitet	Berenberg	Buy
2020-10-28	Eingeleitet	Northland Capital	Outperform
2020-07-14	Eingeleitet	Cowen	Outperform
2020-07-14	Eingeleitet	Goldman	Neutral
2020-07-14	Eingeleitet	Morgan Stanley	Overweight
2020-07-14	Eingeleitet	Piper Sandler	Overweight

Alle ansehen

Repare Therapeutics Inc Aktie (RPTX) Neueste Nachrichten

04:27 AM

Repare signs out-licensing deal with DCx Biotherapeutics - Yahoo Finance

04:27 AM

May 01, 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics - CRISPR Medicine News

May 01, 2025

Arvinas ends plans for two Phase 3 breast cancer trials; Phathom makes cuts - Endpoints News

May 01, 2025

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates - BioSpace

May 01, 2025

Apr 29, 2025

Repare Therapeutics Inc.'s (NASDAQ:RPTX) Shares Bounce 30% But Its Business Still Trails The Industry - simplywall.st

Apr 29, 2025

Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025

Apr 25, 2025

Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Significant Drop in Short Interest - MarketBeat

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025 - CRISPR Medicine News

Apr 25, 2025

Repare Therapeutics Announces Six Abstracts Accepted for Present - GuruFocus

Apr 25, 2025

Apr 24, 2025

Do investors need to be concerned about Repare Therapeutics Inc (RPTX)? - uspostnews.com

Apr 24, 2025

Insider’s View: Deciphering Repare Therapeutics Inc (RPTX)’s Financial Health Through Ratios - DWinneX

Apr 24, 2025

Apr 23, 2025